Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus HALOTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus HALOTEX.
FULVICIN-U/F vs HALOTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal